Figure 2
From: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
(a) Dose-dependent inhibition of mantle cell proliferation (Jeko) and diffuse large B-cell lymphoma cell proliferation (DHL6) with the mTOR inhibitor everolimus. (b) Treatment of three MCL cell lines with everolimus has little effect on cell survival.
